Interleukin-6 and soluble intercellular adhesion molecule-1 in renal cancer patients and cultured renal cancer cells

Urologic Oncology

Volumn 3, Issue 2, 1997, Pages 51-58

  Favaro, Daniela ^a   Santarosa, Manuela ^a   Quaia, Michele ^a   Galligioni, Enzo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cultured cells; Interleukin 6 soluble intercellular adhesion molecule 1 (ICAM 1); Renal cell carcinoma; Serum levels

Indexed keywords

ALPHA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030856159     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(97)00036-7     Document Type: Article

References (34)

1. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1.
2. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature (Lond) 1988;332:83-6.
3. Shimizu S, Hirano T, Yoshioka K, et al. IL-6 dependent growth of a Lennert's lymphoma-derived T cell line (KT3). Blood 1988;72:1826-30.
4. Chen L, Mory Y, Zilberstein A, Revel M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-b2. Proc Natl Acad Sci USA 1988; 85:8037-41.
5. Miki S, Iwano M, Miki Y, et al. IL-6 functions as an autocrine growth factor in renal carcinomas. FEBS Lett 1989;250:607-10.
6. Koo AS, Armstrong A, Bochner B, et al. Interleukin-6 and renal cell cancer: Production, regulation, and growth effects. Cancer Immunol Immunother 1992;35:97-105.
7. Serve H, Steinhauser G, Oberberg B, Flegel WA, Northoff H, Berdell W. Studies on the interaction between interleukin 6 and human malignant non hematopoietic cell lines. Cancer Res 1991;51:3862-6.
8. Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317.
9. Santarosa M, Favaro D, Quaia M, et al. Expression and release of intercellular adhesion molecule-1 in renal-cancer patients. Int J Cancer 1995;62:1-5.
10. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-12.
11. Rothlein R, Czajkowski M, O'Neill MM, Marlin SD, Mainolfi E, Merluzzi VJ. Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. J Immunol 1988;141:1665-9.
12. Becker JC, Dummer R, Hartmann AA, Burh G, Schmidt RE. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-γ and tumor necrosis factor-α. J Immunol 1991;147: 4398-401.
13. Giavazzi R, Chirivi RGS, Garofalo A, Rambaldi A, Hemingway I, Pigott R. Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. Cancer Res 1992;52:2628-30.
14. Schwaeble W, Kerlin M, Meyer Zum Buschenfelde KH, Dippold W. De novo expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in pancreas cancer. Int J Cancer 1993;53:328-33.
15. Hutchins D, Steel MC. Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int J Cancer 1994;58:80-4.
16. Galligioni E, Quaia M, Spada A, et al. Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells. Int J Cancer 1993;55:380-5.
17. Favaro D, Santarosa M, Quaia M, et al. Soluble intercellular adhesion molecule-1 and serum cytokines in melanoma patients treated with liposomes containing muramyl tripeptide. Tumori 1995;81:185-90.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Takenawa J, Kanako Y, Fukyumoto M, et al. Enhanced expression of IL-6 in primary human renal cell carcinoma. J Natl Cancer Inst 1991;83:1668-72.
20. Blay JY, Schemann S, Favrot MC. Local production of interleukin 6 by renal adenocarcinoma in vivo. J Natl Cancer Inst 1994;86:238.
21. Stadler WM, Richards JM, Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: Correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst 1992;84:1835-6.
22. Dosquet C, Schaetz A, Faucher C, et al. Tumour necrosis factor-a, interleukin-1b and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 1994;30A:162-7.
23. Johnson JP, Stade BG, Holzmann B, Schwaeble W, Riethmuller G. De novo expression of intercellular adhesion molecule-1 in melanoma correlates with increased risk of metastasis. Proc Nat Acad Sci 1989;86:641-4.
24. Altomonte M, Carbone A, Bertola G, Colombatti A, Ferrone S, Maio M. Functional role of cell-adhesion molecule in the cell-mediated cytotoxicity of human melanoma cells [abstract]. Proc AACR 1992;33:297.
25. Webb DSA, Mostowski HS, Gerrard TL. Cytokine-induced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocyte-mediated lysis. J Immunol 1991;146:3682-6.
26. Vanky F, Wang P, Patarroyo M, Klein E. Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class-I antigens on tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother 1990;31:19-27.
27. Harning R, Mainolfi E, Bystryn JC, Henn M, Merluzzi VJ, Rothlein R. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 1991; 51:5003-5.
28. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T-cells. J Immunol 1988;141: 1543-9.
29. Mulè JJ, Custer MC, Travis WD, Rosenberg SA. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 1992;148:2622-9.
30. Tanner J, Tosato G. Impairment of natural killer functions by interleukin-6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 1991;88:239-47.
31. Aderka D, Le J, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989;143:3517-24.
32. Zhou D, Munster A, Winchurch RA. Pathologic concentrations of interleukin 6 inhibit T cell responses via induction of activation of TGF-β. FASEB 1991;5:2582-5.
33. Lu C, Vickers MF, Kerbel RS. Interleukin 6: A fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumour progression. Proc Natl Acad Sci USA 1992;89:9215-9.
34. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993;120:1281-8.